EverHint Signal — EMA10 × EMA30 Crossover — December 30, 2025

What This Signal Is (Quick)

The EMA10 × EMA30 crossover strategy tracks when the 10-day exponential moving average crosses the 30-day exponential moving average. It's designed to catch short-to-medium term momentum shifts before they become obvious.

Buy signals fire when EMA(10) crosses above EMA(30) on today's close—short-term momentum is overtaking the medium-term trend, suggesting acceleration in upward price movement. These setups are ideal for swing trades with 1-4 week holding periods.

Sell signals fire when EMA(10) crosses below EMA(30)—short-term momentum weakens below the medium-term trend, suggesting deceleration or reversal. These can signal exit points for longs or potential short entries.

This strategy is more responsive than the classic EMA10 × SMA50 setup, generating more frequent signals but also carrying higher whipsaw risk in choppy markets. This is an experimental scanner—signals are for educational use, back-testing, and research, not direct trading recommendations.

How We Ranked Today (Reader Version)

Today's signals are ranked primarily by RSI(14), with lower RSI values ranking higher for buy signals (more oversold = better risk/reward potential on mean reversion). We overlay three additional data layers to provide context:

• Insider Net (USD): Net insider buying (purchases minus sales) over the last 90 days. Positive = net buying (bullish signal), negative = net selling (bearish signal). Awards, exercises, and tax payments are excluded—only open-market purchases and sales count.

• Days → Earnings: Days until the next earnings report. Closer earnings = higher event risk and potential volatility.

• Analyst Coverage: Average EPS and revenue estimates provide context on Wall Street expectations.

These signals are for educational use and back-testing. They're not financial advice. Do your own due diligence.

📈 Buy-Side Signals

Today's scanner caught 13 buy signals where EMA(10) crossed above EMA(30), spanning Energy, Real Estate, Technology, Healthcare, and Communication Services.

Field Notes:

• RSI(14): Relative Strength Index on a 0-100 scale. Below 30 = oversold (potential bounce), above 70 = overbought (extended). Our buy signals range from 33.83 (RIG) to 86.38 (CUZ), with most clustered in the 40-60 range—not deeply oversold, but showing momentum shift from neutral zones.

• Energy Concentration: Three of the top five buy signals are in Energy (RIG, AR, CNQ), reflecting sector-specific momentum as oil and gas names show technical strength heading into year-end.

• Insider Activity: Notable net insider selling at SNAP (-$8.59M), reflecting CEO Evan Spiegel's programmatic sales. HubSpot shows net buying (+$1.19M), though modest relative to market cap.

• Earnings Proximity: IP and ATGE both report in 30 days—consider tightened stops given event risk. SRAD and WRD have longer runways (78 and 73 days respectively).

Recent Headlines

• RIG - Transocean: Officers sold shares at $4.00 in late October, indicating potential profit-taking before recent momentum shift.

• AR - Antero Resources: Featured in multiple "favorite picks for 2026" articles from Seeking Alpha, with analysts highlighting strong momentum scores despite bearish positioning in the energy sector broadly.

• CNQ - Canadian Natural: Motley Fool noted CNQ as a top income play for 2026, emphasizing dividend durability and low-cost assets. Zacks highlighted the stock's appeal for income investors despite broader energy weakness.

• SNAP - Snap Inc.: CEO Evan Spiegel executed large programmatic sales in December (1.26M shares at $8.00), but also granted significant equity awards to executive team, including 2.99M shares to new General Counsel Zachary Briers.

• HUBS - HubSpot: Director Brian Halligan sold 8,265 shares at $446.98 in October, while CFO Kathryn Bueker sold 615 shares at $500 in early October—profit-taking at higher levels.

• ATGE - Adtalem Global Education: Zacks featured ATGE as a "strong growth stock" with positive Style Score momentum, highlighting the company's education vertical strength.

• CUZ - Cousins Properties: Zacks analysis compared CUZ favorably to Vornado, noting Sun Belt demand and stronger growth visibility. Multiple analysts maintain "Moderate Buy" ratings with 10 analysts covering the stock.

• BROS - Dutch Bros: Though BROS is on the sell-side today, recent news highlighted aggressive expansion plans (160 new stores in 2025) and strong transaction growth, suggesting the crossover may reflect profit-taking after a strong run.

📉 Sell-Side Signals

Today's scanner identified 21 sell signals where EMA(10) crossed below EMA(30), spanning Healthcare, Technology, Consumer Cyclical, Industrials, and Financial Services.

Field Notes:

• RSI Distribution: Sell signals show wider RSI dispersion, from deeply oversold (RARE at 13.78, MRUS at 11.87) to neutral (BROS at 62.67). The deeply oversold names may be catching falling knives—momentum is clearly negative.

• Healthcare Weakness: Five healthcare names on the sell-side (RARE, GRAL, CORT, CYTK, MRUS), with GRAL showing massive insider selling (-$79.85M, primarily ILLUMINA, INC. dumping 1M shares at $79.85 in November).

• Technology Rotation: Six tech names crossed below (SANM, TEL, POWI, NXT, WEX), plus one tech on the buy-side. Sector rotation in play.

• Insider Activity: MRUS shows massive net insider buying (+$34.15M) from 10% owner GENMAB A/S purchasing shares in December. Despite this, the sell signal suggests near-term technical weakness. GRAL shows opposite pattern—massive selling by ILLUMINA.

• Earnings Risk: FAST reports in just 20 days, SANM in 27 days, NXT in 28 days—all approaching catalysts with negative momentum.

Recent Headlines

• RARE - Ultragenyx Pharmaceutical: No specific news in the past week; deeply oversold RSI suggests continued selling pressure.

• GRAL - GRAIL: Major 10% owner ILLUMINA, INC. sold 1M shares at $79.85 in November, representing significant insider selling pressure. President Joshua Ofman also sold shares across multiple transactions.

• CORT - Corcept Therapeutics: CEO Joseph Belanoff executed large tax-related transactions in late December (306,846 shares for taxes, 550,000 option exercises). Multiple insider sales throughout Q4, including a $3.19M sale by CEO on December 1st.

• BROS - Dutch Bros: Despite sell signal, recent articles highlight the company as a "favorite non-tech growth play" with 15% new store growth and strong brand momentum. Analysts note 160 new stores planned for 2025. Stock nearly tripled from 2023 lows. Multiple insider sales in November (~$18M combined from 10% owners Travis Boersma and related entities).

• CYTK - Cytokinetics: Director Wendell Wierenga sold 20,000 shares at $66.14 in late December. Director Edward Kaye sold shares across multiple transactions. Unusual options activity noted with 103% increase in call option purchases on December 23rd.

• TEL - TE Connectivity: CEO Terrence Curtin sold significant shares in mid-December (26,102 shares combined at ~$225-230). Multiple executives received equity awards and sold shares for taxes in mid-December.

• MRUS - Merus: 10% owner GENMAB A/S purchased 278,441 shares totaling $27.01M in mid-December at $97/share, showing strong insider confidence despite technical sell signal. Multiple insiders participated in tender offers and returned shares in December.

• FAST - Fastenal: Director Sam Hsu purchased 1,000 shares at $49.58 in November, showing insider confidence. Reports earnings in 20 days.

• WING - Wingstop: Director Kilandigalu Madati sold 269 shares at $259.97 in November, minor insider activity.

Vlad's Take (EverHint)

Market backdrop: U.S. equities showed mixed action on December 30th. The S&P 500 dipped -0.06% to 6,896.25, while the Nasdaq slid -0.20% to 23,419.08. The Dow underperformed with a -0.14% decline to 48,367.05. Small-caps lagged slightly with the Russell 2000 down -0.77% to 2,500.59, suggesting some defensive positioning as year-end approaches. The VIX closed at 14.32, down slightly from 14.43—indicating low to normal volatility, not panic. Treasury yields edged down (10Y at 4.124%, -0.41%), providing modest support for rate-sensitive sectors. Crypto showed strength: Bitcoin +1.20% to $88,155 and Ethereum +0.86% to $2,959. Overall: Muted, consolidation-like environment heading into year-end—not aggressively bullish, but not fearful either.

For today's EMA10×EMA30 crossovers, this matters. With VIX at 14.32, there's room for swing trades without elevated whipsaw risk. However, the small-cap underperformance and mixed signals across major indices suggest sector rotation rather than broad risk-on momentum.

Buy-side highlights: The Energy concentration (RIG, AR, CNQ) is interesting—oil and gas names are showing technical strength despite sector-wide negativity in 2024-2025. If you're contrarian and believe energy is setting up for 2026, these crossovers align with that thesis. RIG at $4.13 with RSI of 33.83 is technically oversold, suggesting a potential bounce if momentum holds. SNAP's sell signal (insider selling) is worth noting, but the $8.07 entry could be compelling if you believe in the turnaround story. HUBS at $405.83 is pricey but showing momentum—consider tiered entries given the premium valuation.

Sell-side caution: The deeply oversold healthcare names (RARE at RSI 13.78, MRUS at 11.87) are catching falling knives. Yes, MRUS has massive insider buying from GENMAB (+$34.15M), but the technical picture is ugly—wait for momentum to stabilize before jumping in. GRAL's -$79.85M insider selling from ILLUMINA is a massive red flag. BROS is the most interesting sell signal—the fundamentals are strong (expansion, same-store sales growth), but the technical breakdown after a huge run suggests profit-taking. If you're long BROS, consider trimming or tightening stops. If you're watching, wait for the dust to settle.

Earnings risk: FAST (20 days), SANM (27 days), NXT (28 days), CVBF (29 days), TEL (29 days), IP (30 days), ATGE (30 days), and CACC (30 days) all report within a month. If you're trading these, consider shorter-term positions or tighter stops. The approaching catalysts add volatility.

Bottom line: This is a tiered entry environment. Don't go all-in on first signals. The market is in consolidation mode, sector rotation is active, and we're at year-end (low volume, erratic moves). For buy signals, scale in—25% now, 25% if the trend confirms, 50% reserved for pullbacks. For sell signals, respect the momentum breakdown. If you're long these names, tighten stops or trim positions. And always, always layer your own due diligence on top of technical signals.

Independent, data-driven signals.
No hype. No promotions. Just experimental market research from EverHint.

This is not financial advice. Do your own due diligence.
See https://www.everhint.com/disclaimer/ and https://www.everhint.com/faqs/

🎯 If this breakdown was useful, feel free to like, share, or subscribe. Every bit of support matters.